Browse studies

Find your next paid study

1 recruiting study matching your filters

A First-in-human Study of RLY-8161 for Treatment of Advanced NRAS-Mutant Melanoma and Other Solid Tumors

This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and prel…

Advanced NRAS-Mutant MelanomaAdvanced NRAS-Mutant Solid TumorsNRAS Mutation+8 more

Estimated

~$10 – $8,750

Relay Therapeutics, Inc.NCT07584226